Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.

Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J.

Mol Cancer Ther. 2005 Sep;4(9):1311-9.

2.

Hsp90 as a therapeutic target in prostate cancer.

Solit DB, Scher HI, Rosen N.

Semin Oncol. 2003 Oct;30(5):709-16. Review.

PMID:
14571418
3.

Hsp90: an emerging target for breast cancer therapy.

Beliakoff J, Whitesell L.

Anticancer Drugs. 2004 Aug;15(7):651-62. Review.

PMID:
15269596
4.

Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.

Georgakis GV, Younes A.

Future Oncol. 2005 Apr;1(2):273-81. Review.

PMID:
16555999
5.

Heat shock protein 90 inhibition in lung cancer.

Shimamura T, Shapiro GI.

J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S152-9. doi: 10.1097/JTO.0b013e318174ea3a. Review.

6.

Targeting the androgen receptor pathway in prostate cancer.

Chen Y, Sawyers CL, Scher HI.

Curr Opin Pharmacol. 2008 Aug;8(4):440-8. doi: 10.1016/j.coph.2008.07.005. Epub 2008 Aug 12. Review.

7.

Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer.

Albany C, Hahn NM.

Asian J Androl. 2014 May-Jun;16(3):359-63. doi: 10.4103/1008-682X.126400. Review.

8.

Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development.

Hsieh AC, Small EJ, Ryan CJ.

Lancet Oncol. 2007 Oct;8(10):933-9. Review.

PMID:
17913662
9.

Ganetespib: research and clinical development.

Jhaveri K, Modi S.

Onco Targets Ther. 2015 Jul 24;8:1849-58. doi: 10.2147/OTT.S65804. eCollection 2015. Review.

10.

A perspective on the role of estrogen in hormone-induced prostate carcinogenesis.

Bosland MC.

Cancer Lett. 2013 Jun 28;334(1):28-33. doi: 10.1016/j.canlet.2012.08.027. Epub 2012 Aug 29. Review.

11.

Androgen receptor: good guy or bad guy in prostate cancer invasion?

Baldi E, Bonaccorsi L, Forti G.

Endocrinology. 2003 May;144(5):1653-5. Review. No abstract available. Erratum in: Endocrinology. 2003 Jul;144(7):2901.

PMID:
12697667
12.

Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer Cells.

Pathak R, Philizaire M, Mujtaba S.

Cancers (Basel). 2015 Aug 19;7(3):1622-42. doi: 10.3390/cancers7030854. Review.

13.

SGTA: a new player in the molecular co-chaperone game.

Philp LK, Butler MS, Hickey TE, Butler LM, Tilley WD, Day TK.

Horm Cancer. 2013 Dec;4(6):343-57. doi: 10.1007/s12672-013-0151-0. Epub 2013 Jul 2. Review.

PMID:
23818240
14.

p30 DBC is a potential regulator of tumorigenesis.

Kim JE, Chen J, Lou Z.

Cell Cycle. 2009 Sep 15;8(18):2932-5. Epub 2009 Sep 8. Review.

Items per page

Supplemental Content

Write to the Help Desk